Clinical Study to Evaluate the Efficacy of an Anti-Fungal Supplement

CanXida

Status: Completed

Conditions: Candida Infection; Candida Systemic; Candida Albicans Infection

Treatments: Other: Placebo; Dietary Supplement: CanXida Remove (Formula RMV)

Study type: Interventional

Funder types: Industry

Identifiers

NCT06146504

20369

Details and patient eligibility

About

This is a virtual, double-blind, two-arm, randomized, placebo-controlled clinical trial that will last 12 weeks. Participants will take the CanXida Remove Candida Cleansing Formula RMV or a placebo product daily and complete questionnaires at Baseline, Week 6, and Week 12. Candida microbiome testing will be conducted via stool sample at Baseline and Week 12.

The participants will all be blinded to the name of the test brand.

Enrollment: 60 patients

Sex: Female

Ages: 18 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Aged between 18-50.

2. Female.

3. Self-reported recurrent vaginal issues, including:

   • Itching and irritation in and around the vaginal area.
   • Burning sensation during urination or sexual intercourse.
   • Abnormal discharge (e.g. thicker, white, and curd-like in appearance, odorless, or with a mild yeasty smell.
   • Redness and swelling of the vulva and surrounding skin
   • Pain or discomfort in the vaginal area or lower abdomen.
   • Urinary tract infections
   • Vaginal thrush

4. May also experience issues with fatigue, lethargy, and gut or digestive issues.

5. Willing to provide two stool samples during the study.

6. Willing to adhere to the study protocol.

7. Willing to avoid introducing any products or any new forms of regular medication or supplements that target candida overgrowth, gut health, or vaginal health for the duration of the study.

Exclusion criteria

1. Anyone with severe chronic conditions including oncological conditions, psychiatric disease, diabetes, or other.
2. Anyone with known severe allergic reactions or is allergic to the test product or placebo ingredients.
3. Currently taking any antibiotics or will be during the trial period.
4. Anymore diagnosed with a sexually transmitted disease within the last three months e.g. Chlamydia, trichomoniasis, gonorrhea, genital herpes
5. Women who are pregnant, breastfeeding, or attempting to become pregnant.
6. Having any planned invasive medical procedures during the study period.
7. Currently participating in any other clinical study.
8. History of substance abuse.
9. Unwilling to follow the study protocol.

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

60 participants in 2 patient groups, including a placebo group

CanXida Supplement

Experimental group

Description:

All participants will adhere to the following treatment regime: Day 1-7: 1 tablet per day Day 8-22: 2 tablets per day Day 23- 84: 3 tablets per day The product should always be taken with the first meal of the day.

Treatment:

Dietary Supplement: CanXida Remove (Formula RMV)

Placebo

Placebo Comparator group

Description:

All participants will adhere to the following treatment regime: Day 1-7: 1 tablet per day Day 8-22: 2 tablets per day Day 23- 84: 3 tablets per day The product should always be taken with the first meal of the day.

Treatment:

Other: Placebo